drugset / Trial / NCT00503022

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

NCT00503022

Phase 1 Completed 20 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.

Timeline

Start
2006-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody Intravenous